Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: Relevance to post-remission therapy

Blood

Volumn 121, Issue 14, 2013, Pages 2734-2738

  Pratcorona, Marta ^a   Brunet, Salut ^b   Nomdedéu, Josep ^b   Ribera, Josep Maria ^c   Tormo, Mar ^d   Duarte, Rafael ^e   Escoda, Lourdes ^f   Guàrdia, Ramon ^g   De Llano, M Paz Queipo ^h   Salamero, Olga ⁱ   Bargay, Joan ^j   Pedro, Carmen ^k   Martí, Josep Maria ^l   Torrebadell, Montserrat ^a   Díaz Beyá, Marina ^a   Camós, Mireia ^m   Colomer, Dolors ^a   Hoyos, Montserrat ^b   Sierra, Jorge ^b   Esteve, Jordi ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL DURAN I REYNALS   (Spain)

^f HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^g HOSPITAL JOSEP TRUETA   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j HOSPITAL SON LLÀTZER   (Spain)

^k HOSPITAL DEL MAR   (Spain)

^l HOSPITAL MÚTUA DE TERRASSA   (Spain)

^m HOSPITAL SANT JOAN DE DÉU   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; NUCLEOPHOSMIN; ANTINEOPLASTIC AGENT; FLT3 PROTEIN, HUMAN; NUCLEAR PROTEIN;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DE NOVO ACUTE MYELOID LEUKEMIA; FEMALE; GENE MUTATION; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK REDUCTION; ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; DISEASE FREE SURVIVAL; GENE DUPLICATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; PROGNOSIS; RECURRENT DISEASE; REMISSION; RISK FACTOR; TANDEM REPEAT; TREATMENT OUTCOME;

ADULT; ALLELES; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; TANDEM REPEAT SEQUENCES; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84878344487     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-431122     Document Type: Article

References (25)

1. Abu-Duhier FM, Goodeve AC, Wilson GA, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol. 2000;111(1):190-195.
2. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93(9): 3074-3080.
3. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752-1759.
4. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326-4335.
5. Ozeki K, Kiyoi H, Hirose Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood. 2004;103(5): 1901-1908.
6. Gale RE, Green C, Allen C, et al; Medical Research Council Adult Leukaemia Working Party. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776-2784.
7. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001;61(19): 7233-7239.
8. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-2433.
9. Thol F, Damm F, Lüdeking A, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011; 29(21):2889-2896.
10. Gaidzik VI, Schlenk RF, Moschny S, et al. German-Austrian AML Study Group. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood. 2009; 113(19):4505-4511.
11. Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106(12): 3740-3746.
12. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107(10):4011-4020.
13. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005; 106(12):3733-3739.
14. Schlenk RF, Döhner K, Krauter J, et al; German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-1918.
15. de Jonge HJ, Valk PJ, de Bont ES, et al. Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD. Haematologica. 2011;96(9): 1310-1317.
16. Schnittger S, Bacher U, Kern W, et al. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia. 2011;25(8):1297-1304.
17. Schneider F, Hoster E, Unterhalt M, et al. The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype. Blood. 2012;119(19):4383-4386.
18. Grimwade D, Hills RK, Moorman AV, et al; National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3): 354-365.
19. Boissel N, Renneville A, Biggio V, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood. 2005;106(10):3618-3620.
20. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant. 2007; 40(4):381-387.
21. Levis M. FLT3/ITD AML and the law of unintended consequences. Blood. 2011;117(26):6987-6990.
22. Bornhäuser M, Illmer T, Schaich M, et al; AML SHG 96 study group. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood. 2007;109(5):2264-2265, author reply 2265.
23. Brunet S, Labopin M, Esteve J, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol. 2012; 30(7):735-741.
24. Meshinchi S, Arceci RJ, Sanders JE, et al. Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. Blood. 2006;108(1):400, author reply 400-401.
25. Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005; 106(10):3658-3665.